Author, year | Intervention (dose, schedule) | Comparison (description) | Patients (N) | Age (years) | Male (%) | IPSS classification intervention | IPSS classification comparison | Follow-up (months) |
---|---|---|---|---|---|---|---|---|
Azacitidine | ||||||||
 Fenaux, 2009 [10] | Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q 28 days for at least six cycles | BSC, low-dose Ara-C 20 mg/m2, intensive chemotherapy, or mitoxantrone | Intervention: 179 Comparison: 179 | Intervention: 69 (42–83) Comparison: 70 (38–88) | NR | Intermediate-1: 5 (3%) Intermediate-2: 76 (43%) High: 82 (46%) | Intermediate-1: 13 (7%) Intermediate-2: 70 (39%) High: 85 (48%) | 42 |
 Silverman, 2002 [19] | Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q 28 days for at least six cycles | Supportive care with antibiotics and transfusions | Intervention: 99 Comparison: 92 | Intervention: 69 (31–92) Comparison: 67 (35–88) | Intervention: 71.05 Comparison: 63.27 | Low*: 2 (2%) Intermediate-1: 21 (26%) Intermediate-2: 9 (11%) High: 7 (9%) | Low*: 5 (6%) Intermediate-1: 16 (20%) Intermediate-2: 13 (16%) High: 8 (10%) | 53 |
Decitabine | ||||||||
 Kantarjian, 2006 [21] | Decitabine: intravenously 15 mg/m2 Q 8 h for 3 days, every 6 weeks | BSC | Intervention: 89 Comparison: 81 | Intervention: 70 (65–76) Comparison: 70 (62–74) | Intervention: 66.29 Comparison: 70.37 | Intermediate-1: 28 (31%) Intermediate-2: 38 (43%) High: 23 (26%) | Intermediate-1: 24 (30%) Intermediate-2: 36 (44%) High: 21 (26%) | 30 |
 Lubbert, 2011 [11] | Decitabine: intravenously 15 mg/m2 Q 8 h for 3 days, every 6 weeks | BSC | Intervention: 119 Comparison: 114 | Intervention: 69 (60–90) Comparison: 70 (60–86) | Intervention: 63.87 Comparison: 64.04 | Intermediate-1: 8 (6.7%) Intermediate-2: 64 (53.8%) High: 46 (38.7%) | Intermediate-1: 8 (7%) Intermediate-2: 63 (55.3%) High: 42 (36.8%) | 30 |